# A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously

> **NCT02618512** · PHASE1,PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Mucopolysaccharidosis III, Type B (MPS IIIB)
- Sanfilippo B

## Interventions

- **DRUG:** SBC-103

## Key facts

- **NCT ID:** NCT02618512
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10-15
- **Primary completion:** 2017-08-18
- **Final completion:** 2017-08-18
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The Sponsor's decision to terminate the SBC-103 program was reached after review of the data from all interventional clinical studies of SBC-103.
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02618512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02618512, "A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02618512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*